Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Macupatide and eloralintide multiple-dose study in Japanese adults with obesity or overweight without type 2 diabetes
jRCT2051260163Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Trial of macupatide and eloralintide in obesity and Overweight (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of participants with one or more serious adverse events considered related to study drug administration. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
macupatideeloralintide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on jRCT2051260163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051260163.